2027 Co-op Product Biochemistry
Regeneron Pharmaceuticals
Summary
Regeneron is currently seeking multiple 2027 Co-ops to join our Product Biochemistry team, which develops and applies analytical and biophysical characterization methods to understand the structure, stability, and function of Regeneron's biologic and oligonucleotide-based medicines.
Job description
What you'll do
- Develop and apply analytical methods to characterize therapeutic proteins, antibodies, and oligonucleotide-based biotherapeutics
- Evaluate protein biophysical properties such as size, charge, and structural stability using light scattering, chromatography, and electrophoretic techniques
- Assess antibody developability properties, including hydrophobicity, surface charge, and self-association, using high-throughput screening assays
- Support structural studies of nucleic acid-based therapeutics using spectroscopic techniques
- Build automated workflows to streamline analytical data processing and reporting
- Analyze and interpret experimental data using statistical tools to support scientific decision-making
- Document experimental procedures, results, and method performance
- Collaborate with scientists across analytical development and drug discovery teams
Relevant majors
Biology, Chemistry, Biomedical/Chemical Engineering
Requirements
- Must be enrolled in, or accepted to, an academic program pursuing an Undergraduate or Graduate degree (and be returning to school the semester following the position or graduating after the position)
- Must be able to commit to 40 hours per week from January-August, May/June-December, or August-December
- Demonstrated leadership in areas such as campus activities, clubs, sports, current or previous work, or within the community preferred
- Cumulative GPA of 3.0 or higher preferred
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.